WINTERMUTE BIOMEDICAL RECEIVES ETHICS APPROVAL FOR PHASE IB CLINICAL TRIAL OF SOLEXAN IN SHINGLES PATIENTS

Breaking Ground in Shingles Treatment: Wintermute Biomedical Advances to Clinical Trials … Wintermute Biomedical is excited to report that in December 2023 they have received full approval to conduct a Phase IB clinical trial in Australia using their first-in-class topical antiviral, Solexan. Solexan has been developed over the last 12 years by Wintermute Biomedical as a […]

Continue Reading

REVOLUTIONARY VEIN TREATMENT DOCTORS NOW SERVING TAMPA BAY AREA

Vein911® Vein Treatment Centers welcomes the additions of Drs. Brian Pink and Arian Moshref to their award-winning, world-renowned vein care specialist team. They join the multi-location practice founded by Dr. Chris Pittman to better serve Tampa Bay residents suffering from varicose veins, swelling, skin changes, ulcers, restless legs, night cramps, leg discomfort, cosmetic spider veins […]

Continue Reading

PATIENTS DRIVEN TO SELF-DIAGNOSE ONLINE THROUGH INABILITY TO ACCESS GPS, WHILE HUGE DEMAND FOR APPS ON PRESCRIPTION – RESEARCH

More than half of UK adults are self-diagnosing their health problems online rather than seeing a medical professional (55% of adults in the past 6 months). The new research, from Medtech engineering specialists Zühlke, shows this is particularly the case where people have had GP and healthcare access problems (43% in the past 6 months), […]

Continue Reading

VEG POWER LAUNCHES GROUND-BREAKING PUBLIC HEALTH CAMPAIGN TO IMPROVE FAMILIES’ DIETS

Veg Power, the not-for-profit alliance to increase the UK’s vegetable consumption, launched its second ground-breaking public health campaign ‘Simply Veg’ today. Created with the UK’s leading nutrition, child psychology, neurodiversity, food education, culinary and children’s entertainment experts Unique and holistic approach developed by team that has proven success at increasing UK children’s veg consumption New […]

Continue Reading

ABOLERIS PHARMA ANNOUNCES €27.3 MILLION IN SERIES A FINANCING TO ADVANCE ITS NOVEL TREATMENT PARADIGM FOR AUTOIMMUNE AND INFLAMMATORY DISEASES

AbolerIS Pharma (“AbolerIS”), a biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, today announced a €27.3 million Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with participation from SFPI-FPIM, WE, Sambrinvest, Investsud Tech, and Relyens Innovation Santé/Turenne […]

Continue Reading